Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial
Open Access
- 26 July 2025
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 83, 104547
Abstract
No abstract availableKeywords
Funding Information
- Fond National de la Recherche Scientific
This publication has 34 references indexed in Scilit:
- Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast CancerJAMA Network Open, 2023
- Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patientsInternational Journal of Cancer, 2022
- Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancyThe Breast, 2021
- Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†Annals of Oncology, 2020
- Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy – A translational research project of the SUCCESS A studyThe Breast, 2017
- Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancerEuropean Journal of Cancer, 2017
- Premature ovarian insufficiency: the context of long-term effectsJournal of Endocrinological Investigation, 2016
- Menses resumption after cancer treatment–induced amenorrhea occurs early or not at allFertility and Sterility, 2016
- Female age-related fertility declineFertility and Sterility, 2014
- Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancerFertility and Sterility, 2010